MBX Biosciences (MBX) Capital Expenditures (2023 - 2026)
MBX Biosciences has reported Capital Expenditures over the past 4 years, most recently at $437000.0 for Q1 2026.
- Quarterly results put Capital Expenditures at $437000.0 for Q1 2026, down 12.95% from a year ago — trailing twelve months through Mar 2026 was $1.9 million (up 38.9% YoY), and the annual figure for FY2025 was $1.9 million, up 120.71%.
- Capital Expenditures reached $437000.0 in Q1 2026 per MBX's latest filing, down from $793000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $858000.0 in Q4 2024 and bottomed at -$54000.0 in Q3 2024.
- Median Capital Expenditures over the past 4 years was $317000.0 (2025), compared with a mean of $325800.0.
- The largest annual shift saw Capital Expenditures skyrocketed 4666.67% in 2024 before it decreased 12.95% in 2026.
- Over 4 years, Capital Expenditures stood at $18000.0 in 2023, then surged by 4666.67% to $858000.0 in 2024, then decreased by 7.58% to $793000.0 in 2025, then tumbled by 44.89% to $437000.0 in 2026.
- Business Quant data shows Capital Expenditures for MBX at $437000.0 in Q1 2026, $793000.0 in Q4 2025, and $399000.0 in Q3 2025.